NEW YORK, May 21 (Reuters) - Abbott Laboratories Inc said on Wednesday its Humira medicine has maintained maximum effectiveness for a year or longer among roughly 29 percent of Crohn's disease ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

AbbVie's blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients, potentially adding another arrow to the company's post-Humira quiver. The JAK inhibitor helped ...

AbbVie has been following a dependable playbook as it develops its young immunology blockbuster Rinvoq, a follow-up to its aging Humira. Relatively early in its life cycle, five years after it hit the ...

An open-label extension study of the Charm and Gain studies, performed in Abbott labs, demonstrate that patients with moderate-to-severe Crohn's disease who are treated with Humira (adalimumab) ...

SAN FRANCISCO (MarketWatch) -- Abbott Laboratories said Monday that data from a Phase III extended study show that 74% of patients with moderate to severely active Crohn's disease who reached clinical ...

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (ABBV +0.59%) blockbuster immunology drug facing competition. After all, at its peak, Humira brought ...